Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: Results from a nationwide, retrospective inception cohort study

Schizophrenia Bulletin

Volumn 41, Issue 3, 2015, Pages 627-636

  Nielsen, Jimmi ^a,b   Jensen, Signe O W ^b   Friis, Rasmus B ^b   Valentin, Jan B ^b   Correll, Christoph U ^c,d  

^a AALBORG UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

All cause discontinuation; Cohort study; First generation antipsychotics; Hospitalization; Long acting injectable; Risperidone; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LAMOTRIGINE; LITHIUM; NOOTROPIC AGENT; OXCARBAZEPINE; PERPHENAZINE DECANOATE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL DECANOATE; DECANOIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; ICD-10; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DENMARK; HOSPITALIZATION; INJECTION; MIDDLE AGED; OUTCOME ASSESSMENT; REGISTER; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; DECANOATES; DELAYED-ACTION PREPARATIONS; DENMARK; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INJECTIONS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS;

EID: 84928627922     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu128     Document Type: Article

References (34)

1. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiat. 2010;71:1115-1124.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-2196.
3. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiat. 2013;18:53-66.
4. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063-2071.
5. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiat. 2009;70(suppl 4):1-46; quiz 47-48.
6. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196-201.
7. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216-226.
8. Velligan D, Mintz J, Maples N, et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophrenia Bull. 2013;39:999-1007.
9. Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16:306-324.
10. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192-213.
11. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirrorimage studies. J Clin Psychiatry. 2013;74:957-965.
12. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568-575.
13. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
14. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10:23-41.
15. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951-962.
16. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual secondgeneration vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205-1218.
17. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011;39:54-57.
18. Uggerby P, Østergaard SD, Røge R, Correll CU, Nielsen J. The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J. 2013;60:A4578.
19. Uggerby P, Nielsen RE, Correll CU, Nielsen J. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res. 2011;131:120-126.
20. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr Q. 2009;80:241-249.
21. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33:1379-1387.
22. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
23. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
24. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry. 2004;19:219-225.
25. Marinis TD, Saleem PT, Glue P, et al. Switching to longacting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. 2007;40:257-263.
26. Fleischhacker WW. Second-generation antipsychotic longacting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S29-S36.
27. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry. 2010;25:220-229.
28. Covell NH, McEvoy JP, Schooler NR, et al.; Schizophrenia Trials Network. Effectiveness of switching from longacting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012;73:669-675.
29. McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311:1978-1987.
30. Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand. 2010;122:356-366.
31. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Schizophr Bull. 2009;35:855-856.
32. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Clin Ther. 2010;32:108-118.
33. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1002-1008.
34. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol . 2012;15:107-118.